$CPRX
CATALYST PHARMACEUTICALS, INC.

2023 Q4 Form 10-Q Financial Statement

#000119312523273506 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $110.6M $102.7M
YoY Change 81.98% 79.39%
Cost Of Revenue $15.81M $14.17M
YoY Change 41.21% 46.58%
Gross Profit $94.76M $88.52M
YoY Change 91.19% 86.05%
Gross Profit Margin 85.7% 86.2%
Selling, General & Admin $42.04M $33.56M
YoY Change 186.58% 136.89%
% of Gross Profit 44.36% 37.91%
Research & Development $1.972M $83.66M
YoY Change -51.82% 906.76%
% of Gross Profit 2.08% 94.51%
Depreciation & Amortization $9.143M $8.500M
YoY Change 1386.67% 1437.07%
% of Gross Profit 9.65% 9.6%
Operating Expenses $53.07M $117.2M
YoY Change 182.86% 421.52%
Operating Profit $41.69M -$37.19M
YoY Change 35.36% -248.15%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.015M -$833.0K
YoY Change 127.23% -192.04%
Pretax Income $46.71M -$38.02M
YoY Change 41.5% -246.2%
Income Tax $11.86M -$7.257M
% Of Pretax Income 25.4%
Net Earnings $34.84M -$30.76M
YoY Change 36.8% -235.24%
Net Earnings / Revenue 31.51% -29.96%
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share $0.31 -$0.29
COMMON SHARES
Basic Shares Outstanding 106.6M 106.6M
Diluted Shares Outstanding 106.6M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $137.6M $121.0M
YoY Change -53.87% -52.75%
Cash & Equivalents $137.6M $121.0M
Short-Term Investments $0.00
Other Short-Term Assets $12.54M $14.00M
YoY Change 143.02% 270.76%
Inventory $15.64M $9.035M
Prepaid Expenses
Receivables $53.51M $48.05M
Other Receivables $0.00 $0.00
Total Short-Term Assets $219.3M $192.0M
YoY Change -31.63% -30.51%
LONG-TERM ASSETS
Property, Plant & Equipment $1.195M $1.186M
YoY Change 41.09% 34.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.49M $12.90M
YoY Change
Other Assets $36.54M $37.40M
YoY Change 94.95% 86.65%
Total Long-Term Assets $250.8M $221.2M
YoY Change 357.36% 289.4%
TOTAL ASSETS
Total Short-Term Assets $219.3M $192.0M
Total Long-Term Assets $250.8M $221.2M
Total Assets $470.1M $413.2M
YoY Change 25.15% 24.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.80M $4.598M
YoY Change 272.2% 81.81%
Accrued Expenses $61.27M $53.21M
YoY Change 14.28% 26.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $76.06M $57.81M
YoY Change 32.08% 29.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.982M $3.575M
YoY Change -78.8% -75.76%
Total Long-Term Liabilities $2.982M $3.575M
YoY Change -78.8% -75.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $76.06M $57.81M
Total Long-Term Liabilities $2.982M $3.575M
Total Liabilities $82.23M $64.66M
YoY Change 9.34% 2.52%
SHAREHOLDERS EQUITY
Retained Earnings $121.3M $86.43M
YoY Change 143.22% 254.34%
Common Stock $107.0K $107.0K
YoY Change 1.9% 2.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $387.9M $348.5M
YoY Change
Total Liabilities & Shareholders Equity $470.1M $413.2M
YoY Change 25.15% 24.04%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $34.84M -$30.76M
YoY Change 36.8% -235.24%
Depreciation, Depletion And Amortization $9.143M $8.500M
YoY Change 1386.67% 1437.07%
Cash From Operating Activities $55.65M $45.20M
YoY Change 38.85% 9.44%
INVESTING ACTIVITIES
Capital Expenditures $93.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$38.23M -$92.70M
YoY Change 70127.27%
Cash From Investing Activities -$38.32M -$92.80M
YoY Change 70203.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -665.0K -10.10M
YoY Change -129.52% -353.51%
NET CHANGE
Cash From Operating Activities 55.65M 45.20M
Cash From Investing Activities -38.32M -92.80M
Cash From Financing Activities -665.0K -10.10M
Net Change In Cash 16.66M -57.70M
YoY Change -60.63% -227.79%
FREE CASH FLOW
Cash From Operating Activities $55.65M $45.20M
Capital Expenditures $93.00K $0.00
Free Cash Flow $55.55M $45.20M
YoY Change 38.62% 9.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001369568
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33057
dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0837053
dei Entity Address Address Line1
EntityAddressAddressLine1
355 Alhambra Circle
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 801
dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
dei City Area Code
CityAreaCode
305
dei Local Phone Number
LocalPhoneNumber
420-3200
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106611456
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120971000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298395000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48049000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10439000
CY2023Q3 us-gaap Inventory Net
InventoryNet
9035000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6805000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13962000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5167000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
192017000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
320806000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2575000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2770000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1186000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
847000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
167108000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32471000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
37428000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
18736000
CY2023Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
12897000
CY2022Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
0
CY2023Q3 us-gaap Assets
Assets
413211000
CY2022Q4 us-gaap Assets
Assets
375630000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4598000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3975000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53208000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53613000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
57806000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
57588000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3282000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3575000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14064000
CY2023Q3 us-gaap Liabilities
Liabilities
64663000
CY2022Q4 us-gaap Liabilities
Liabilities
75209000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106605007
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106605007
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105263031
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105263031
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
107000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
261998000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250430000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
86428000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
49862000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
348548000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300421000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
413211000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
375630000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102688000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57244000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
287636000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
153446000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14167000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9665000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36158000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23198000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83662000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8310000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91178000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15696000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33560000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13649000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91674000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42997000
CY2023Q3 cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
8487000
CY2022Q3 cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
518000
cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
23506000
cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
518000
CY2023Q3 cprx Operating Expense
OperatingExpense
139876000
CY2022Q3 cprx Operating Expense
OperatingExpense
32142000
cprx Operating Expense
OperatingExpense
242516000
cprx Operating Expense
OperatingExpense
82409000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-37188000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
25102000
us-gaap Operating Income Loss
OperatingIncomeLoss
45120000
us-gaap Operating Income Loss
OperatingIncomeLoss
71037000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-833000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
905000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2684000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
674000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38021000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
26007000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47804000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
71711000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7257000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3259000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11238000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14103000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30764000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
22748000
us-gaap Net Income Loss
NetIncomeLoss
36566000
us-gaap Net Income Loss
NetIncomeLoss
57608000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106568137
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103318572
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106133077
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102967280
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106568137
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111986025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113751370
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110352214
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30764000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
22748000
us-gaap Net Income Loss
NetIncomeLoss
36566000
us-gaap Net Income Loss
NetIncomeLoss
57608000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-52000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-59000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
162000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
180000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30768000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
22910000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36557000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
57788000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300421000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2177000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1270000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
715000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-477000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29568000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
333661000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2576000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
617000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
722000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-52000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
37762000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
375294000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2955000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
212000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
855000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30764000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
348548000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
206831000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1623000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1102000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
280000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2551000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-305000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13241000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
220221000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1594000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1282000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
429000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
4356000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-20000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
323000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
21619000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
241092000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1621000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3984000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
434000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
162000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
22748000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
270041000
us-gaap Profit Loss
ProfitLoss
36566000
us-gaap Profit Loss
ProfitLoss
57608000
us-gaap Depreciation
Depreciation
232000
us-gaap Depreciation
Depreciation
106000
us-gaap Share Based Compensation
ShareBasedCompensation
10000000
us-gaap Share Based Compensation
ShareBasedCompensation
5981000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23506000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
518000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
18701000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3652000
cprx Accretion Of Discount
AccretionOfDiscount
-1146000
cprx Accretion Of Discount
AccretionOfDiscount
-17000
cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
195000
cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
184000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
762000
cprx Acquired Research And Development Inventory Expenses From Asset Acquisition
AcquiredResearchAndDevelopmentInventoryExpensesFromAssetAcquisition
4130000
cprx Acquired Inventory Samples Expensed From Asset Acquisition
AcquiredInventorySamplesExpensedFromAssetAcquisition
130000
cprx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
79288000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-568000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
37610000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2718000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1870000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-738000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7219000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-575000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
623000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-239000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2390000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4885000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-252000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-229000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87952000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
75970000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
138000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
cprx Payment In Connection With Asset Acquisition
PaymentInConnectionWithAssetAcquisition
162293000
cprx Payment In Connection With Asset Acquisition
PaymentInConnectionWithAssetAcquisition
10000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
19238000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
79288000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
13465000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-255184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9209000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
529000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
20000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2099000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6368000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
6907000
cprx Payment Of Liabilities Arising From Asset Acquisition
PaymentOfLiabilitiesArisingFromAssetAcquisition
11762000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10192000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-177424000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
84620000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298395000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171445000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120971000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
256065000
us-gaap Income Taxes Paid
IncomeTaxesPaid
41663000
us-gaap Income Taxes Paid
IncomeTaxesPaid
6344000
us-gaap Interest Paid Net
InterestPaidNet
650000
cprx Liabilities Arising From Asset Acquisition
LiabilitiesArisingFromAssetAcquisition
1915000
cprx Liabilities Arising From Asset Acquisition
LiabilitiesArisingFromAssetAcquisition
27699000
us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Description of Business. </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage biopharmaceutical company focused on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing,</div> developing, and commercializing novel high-quality medicines for patients living with rare diseases and diseases that are difficult to treat. With exceptional patient focus, the Company is committed to developing and commercializing innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> medicines that address rare neurological and epileptic diseases. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s New Drug Application for FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food &amp; Drug Administration (FDA), and FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> is commercially available in the United States as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals. Finally, in the third quarter of 2022, the FDA approved the Company’s sNDA approving an expansion of the FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> label to include pediatric patients (ages six and older). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the United States rights to FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> on January 24, 2023 and the Company is marketing FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> in the United States. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2023, the Company completed its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne muscular dystrophy (DMD). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, the Company will hold North American rights for any future approved indications of vamorolone. Vamorolone has previously received FDA Orphan Drug and Fast Track designations. Subsequent to quarter end, on October 26, 2023, AGAMREE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> (vamorolone) was approved by the FDA for commercialization in the U.S. See Note 17 (Subsequent Events). </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its products. The Company incurred operating losses in each period from inception and started reporting operating income during the year ended December 31, 2019. The Company has been able to fund its cash needs to date through offerings of its securities and from revenues from sales of its products. See Note 15 (Stockholders’ Equity). </div></div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital Resources </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on forecasts of available cash, the Company believes that it has sufficient resources to support the currently anticipated operations for at least the next 12 months from the date of this report. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous aspects of the coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic that have adversely affected the Company’s business since the beginning of the pandemic. The Company closely monitors the impact of the pandemic on all aspects of its business and takes steps, wherever possible, to lessen those impacts. However, the Company is unable to predict the impact that the coronavirus pandemic will have on its business in future periods. </div>
CY2023Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
12897000
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">USE OF ESTIMATES.</div></div> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </div> </td> </tr> </table>
cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
three months
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0
cprx Share Repurchases
ShareRepurchases
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SHARE REPURCHASES.</div></div> In March 2021, the Company’s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $40 million of the Company’s common stock. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock’s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time. </div>
cprx Maximum Amortization Period Of Compensation Cost On Straight Line Basis
MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P3Y
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CONCENTRATION OF RISK. </div></div>The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e., money market funds), investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company sells its product, FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>, in the United States through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2023, the Company had two products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>. The Company expects FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> and the recently acquired product FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> to constitute virtually all of the Company’s product revenue through the end of 2023. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company relies exclusively on third parties to formulate and manufacture FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>, FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div> and any future drug candidates. The commercialization of FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>, FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>, and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>. It also relies on Eisai as its sole source of supply for FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of its drugs. </div>
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106568137
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103318572
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106133077
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102967280
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8667453
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7618293
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7384934
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106568137
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111986025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113751370
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110352214
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12100000
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
1.13
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
19.02
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1700000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RECLASSIFICATIONS.</div></div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div></td></tr></table>
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
85666000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
20000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2023Q3 cprx Amortized Cost Before Unrealized Gains And Losses
AmortizedCostBeforeUnrealizedGainsAndLosses
85646000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105442000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
32000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2022Q4 cprx Amortized Cost Before Unrealized Gains And Losses
AmortizedCostBeforeUnrealizedGainsAndLosses
105410000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-129000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-762000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
85666000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-568000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-568000
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-568000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-568000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Reclassifications Tax
OtherComprehensiveIncomeLossBeforeReclassificationsTax
4000
CY2023Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
us-gaap Other Comprehensive Income Loss Before Reclassifications Tax
OtherComprehensiveIncomeLossBeforeReclassificationsTax
9000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-130000
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Reclassifications Tax
OtherComprehensiveIncomeLossBeforeReclassificationsTax
-33000
CY2022Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-129000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
162000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-148000
us-gaap Other Comprehensive Income Loss Before Reclassifications Tax
OtherComprehensiveIncomeLossBeforeReclassificationsTax
582000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-762000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
180000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2023Q3 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
1157000
CY2022Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
808000
CY2023Q3 cprx Prepaid Research Fee
PrepaidResearchFee
246000
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
286000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4701000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5543000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4048000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1262000
CY2023Q3 us-gaap Inventory Net
InventoryNet
9035000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6805000
CY2023Q3 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
2010000
CY2022Q4 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1147000
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
3767000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
44000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
307000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1224000
CY2022Q4 cprx Prepaid Research Fee
PrepaidResearchFee
178000
CY2023Q3 cprx Prepaid Commercial Expenses
PrepaidCommercialExpenses
4401000
CY2022Q4 cprx Prepaid Commercial Expenses
PrepaidCommercialExpenses
592000
CY2023Q3 cprx Due From Collaborative And Licencing Arrangements
DueFromCollaborativeAndLicencingArrangements
146000
CY2022Q4 cprx Due From Collaborative And Licencing Arrangements
DueFromCollaborativeAndLicencingArrangements
354000
CY2023Q3 cprx Prepaid Conference And Travel Expenses
PrepaidConferenceAndTravelExpenses
1021000
CY2022Q4 cprx Prepaid Conference And Travel Expenses
PrepaidConferenceAndTravelExpenses
234000
CY2023Q3 cprx Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
701000
CY2022Q4 cprx Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
97000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
206000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
489000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13962000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5167000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
5
CY2023Q3 cprx Operating Lease Liability Under Finance Leases
OperatingLeaseLiabilityUnderFinanceLeases
0
cprx Before Agreement Of Company Leased Spaces
BeforeAgreementOfCompanyLeasedSpaces
7800
cprx After Agreement Of Company Leased Spaces
AfterAgreementOfCompanyLeasedSpaces
10700
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
108000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
108000
us-gaap Operating Lease Cost
OperatingLeaseCost
323000
us-gaap Operating Lease Cost
OperatingLeaseCost
324000
us-gaap Operating Lease Payments
OperatingLeasePayments
379000
us-gaap Operating Lease Payments
OperatingLeasePayments
368000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
67000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
67000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2575000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
406000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1186000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
847000
CY2022Q4 cprx Asset Acquisation Due To Licensor Current
AssetAcquisationDueToLicensorCurrent
13127000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
857000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2770000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
361000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
337000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3282000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3643000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3894000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0451
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0451
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
127000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
522000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
537000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
553000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
570000
CY2023Q3 cprx Lessee Operating Lease Liabilities Payments Due After Year Four
LesseeOperatingLeaseLiabilitiesPaymentsDueAfterYearFour
2027000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4336000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
693000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3643000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
639000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
191712000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24604000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
167108000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
33569000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1098000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32471000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
8487000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
33949000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
33949000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
33949000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
33949000
CY2023Q3 cprx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
22825000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
167108000
CY2023Q3 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P6Y
CY2022Q4 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P14Y
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q3 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
441000
CY2022Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
479000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5328000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1619000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5272000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5132000
CY2023Q3 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
19072000
CY2022Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
20444000
CY2023Q3 cprx Accrued Purchases Current
AccruedPurchasesCurrent
84000
CY2022Q4 cprx Accrued Purchases Current
AccruedPurchasesCurrent
154000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
361000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
337000
CY2023Q3 cprx Accrued Variable Consideration
AccruedVariableConsideration
8452000
CY2022Q4 cprx Accrued Variable Consideration
AccruedVariableConsideration
3381000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
912000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
8702000
CY2023Q3 cprx Asset Acquisation Due To Licensor Current
AssetAcquisationDueToLicensorCurrent
12055000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
374000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
238000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53208000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53613000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3282000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q3 cprx Asset Acquisation Due To Licensor Noncurrent
AssetAcquisationDueToLicensorNoncurrent
3144000
CY2022Q4 cprx Asset Acquisation Due To Licensor Noncurrent
AssetAcquisationDueToLicensorNoncurrent
14064000
CY2023Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
431000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2023Q3 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
6857000
CY2022Q4 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
17621000
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
60065000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
71234000
cprx Period Of Collaboration Agreement
PeriodOfCollaborationAgreement
P10Y
CY2023Q3 cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
CY2022Q3 cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
CY2023Q3 cprx License And Asset Purchase Agreement Payment Made In First Year
LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear
10000000
CY2023Q3 cprx License And Asset Purchase Agreement Payment Made In Second Year
LicenseAndAssetPurchaseAgreementPaymentMadeInSecondYear
10000000
CY2023Q1 cprx Number Of Trading Days From Receipt Of The Notice Letter
NumberOfTradingDaysFromReceiptOfTheNoticeLetter
P45D
cprx Percentage Of Royalty Payable To Net Sales
PercentageOfRoyaltyPayableToNetSales
0.035
cprx Asset Acquisition Consideration Transferred Investments
AssetAcquisitionConsiderationTransferredInvestments
13465000
us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
94978000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.235
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.197
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106605007
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106605007
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105263031
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105263031
CY2023Q3 cprx Number Of Votes Entitlement For Each Share Held By Common Stock Holders
NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders
1
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
6900000
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
6.91
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3810000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2055000
us-gaap Share Based Compensation
ShareBasedCompensation
10000000
us-gaap Share Based Compensation
ShareBasedCompensation
5981000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12145818
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001193125-23-273506-index-headers.html Edgar Link pending
0001193125-23-273506-index.html Edgar Link pending
0001193125-23-273506.txt Edgar Link pending
0001193125-23-273506-xbrl.zip Edgar Link pending
cprx-20230930.xsd Edgar Link pending
d540129d10q.htm Edgar Link pending
d540129dex311.htm Edgar Link pending
d540129dex312.htm Edgar Link pending
d540129dex321.htm Edgar Link pending
d540129dex322.htm Edgar Link pending
cprx-20230930_cal.xml Edgar Link unprocessable
cprx-20230930_def.xml Edgar Link unprocessable
cprx-20230930_lab.xml Edgar Link unprocessable
cprx-20230930_pre.xml Edgar Link unprocessable
d540129d10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending